180 related articles for article (PubMed ID: 34452351)
1. Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype.
Morsica G; Vercesi R; Hasson H; Messina E; Uberti-Foppa C; Bagaglio S
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452351
[TBL] [Abstract][Full Text] [Related]
2. A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.
Bagaglio S; Hasson H; Peano L; Vercesi R; Messina E; Galli A; Foppa CU; Morsica G
Viruses; 2020 Feb; 12(3):. PubMed ID: 32121164
[TBL] [Abstract][Full Text] [Related]
3. Prevalence of naturally occurring NS5A resistance-associated substitutions in patients infected with hepatitis C virus subtype 1a, 1b, and 3a, co-infected or not with HIV in Brazil.
Malta F; Gaspareto KV; Lisboa-Neto G; Carrilho FJ; Mendes-Correa MC; Pinho JRR
BMC Infect Dis; 2017 Nov; 17(1):716. PubMed ID: 29132303
[TBL] [Abstract][Full Text] [Related]
4. Net emergence of substitutions at position 28 in NS5A of hepatitis C virus genotype 4 in patients failing direct-acting antivirals detected by next-generation sequencing.
Nguyen T; Akhavan S; Caby F; Bonyhay L; Larrouy L; Gervais A; Lebray P; Poynard T; Calmus Y; Simon A; Valantin MA; Calvez V; Marcelin AG; Todesco E
Int J Antimicrob Agents; 2019 Jan; 53(1):80-83. PubMed ID: 30236959
[TBL] [Abstract][Full Text] [Related]
5. Low level of baseline resistance in recently HCV-infected men who have sex with men with high-risk behaviours.
Nguyen T; Valantin MA; Delaugerre C; Amiel C; Netzer E; L'Yavanc T; Ohayon M; Valin N; Day N; Kreplak G; Pialoux G; Calvez V; Molina JM; Marcelin AG; Todesco E
J Glob Antimicrob Resist; 2021 Mar; 24():311-315. PubMed ID: 33540082
[TBL] [Abstract][Full Text] [Related]
6. Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
Eltahla AA; Rodrigo C; Betz-Stablein B; Grebely J; Applegate T; Luciani F; Schinkel J; Dore GJ; Page K; Bruneau J; Morris MD; Cox AL; Kim AY; Shoukry NH; Lauer GM; Maher L; Hellard M; Prins M; Lloyd AR; Bull RA;
J Viral Hepat; 2017 Jan; 24(1):37-42. PubMed ID: 27666440
[TBL] [Abstract][Full Text] [Related]
7. Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the
McPhee F; Ueland J; Vellucci V; Bowden S; Sievert W; Zhou N
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30718256
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
9. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J; Müllhaupt B; Buggisch P; Graf C; Peiffer KH; Matschenz K; Schattenberg JM; Antoni C; Mauss S; Niederau C; Discher T; Trauth J; Dultz G; Schulze Zur Wiesch J; Piecha F; Klinker H; Müller T; Berg T; Neumann-Haefelin C; Berg CP; Zeuzem S; Sarrazin C; ; ; ;
J Hepatol; 2023 Jan; 78(1):57-66. PubMed ID: 36031158
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.
Bertoli A; Sorbo MC; Aragri M; Lenci I; Teti E; Polilli E; Di Maio VC; Gianserra L; Biliotti E; Masetti C; Magni CF; Babudieri S; Nicolini LA; Milana M; Cacciatore P; Sarmati L; Pellicelli A; Paolucci S; Craxì A; Morisco F; Palitti VP; Siciliano M; Coppola N; Iapadre N; Puoti M; Rizzardini G; Taliani G; Pasquazzi C; Andreoni M; Parruti G; Angelico M; Perno CF; Cento V; Ceccherini-Silberstein F;
Sci Rep; 2018 Jun; 8(1):8988. PubMed ID: 29895871
[TBL] [Abstract][Full Text] [Related]
11. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
[TBL] [Abstract][Full Text] [Related]
12. Naturally occurring NS5A and NS5B resistant associated substitutions in HCV and HCV/HIV patients in iranian population.
Ramezani A; Baesi K; Banifazl M; Mohraz M; Khorvash F; Yaran M; Tabarsi P; Dalirrooyfard AH; Motevalli F; Bavand A; Aghakhani A
Clin Res Hepatol Gastroenterol; 2019 Oct; 43(5):594-602. PubMed ID: 31080115
[TBL] [Abstract][Full Text] [Related]
13. Baseline Hepatitis C Virus NS5A Resistance-Associated Polymorphisms in Patients With and Without Human Immunodeficiency Virus Coinfection in Mexico.
Lopez Luis BA; Angulo-Medina L; Rodriguez-Diaz R; Soto-Ramírez LE
Microb Drug Resist; 2021 Sep; 27(9):1195-1202. PubMed ID: 33794105
[No Abstract] [Full Text] [Related]
14. HCV genotype-1 subtypes and resistance-associated substitutions in drug-naive and in direct-acting antiviral treatment failure patients.
Gozlan Y; Ben-Ari Z; Moscona R; Shirazi R; Rakovsky A; Kabat A; Veizman E; Berdichevski T; Weiss P; Cohen-Ezra O; Lurie Y; Gafanovich I; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Zuckerman E; Carmiel-Haggai M; Nimer A; Hazzan R; Maor Y; Kitay-Cohen Y; Shemer-Avni Y; Kra-Oz Z; Schreiber L; Peleg O; Sierra S; Harrigan PR; Mendelson E; Mor O
Antivir Ther; 2017; 22(5):431-441. PubMed ID: 28067632
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of Naturally Occurring Resistance Associated Substitutions in NS3/4AProtease Inhibitors in Iranian HCV/HIV Infected Patients.
Baesi K; Velayati AA; Ashtiani MF; Fakhredini K; Banifazl M; Larijani MS; Basimi P; Ramezani A
Curr HIV Res; 2021; 19(5):391-397. PubMed ID: 34238162
[TBL] [Abstract][Full Text] [Related]
16. High frequency of multiclass HCV resistance-associated mutations in patients failing direct-acting antivirals: real-life data.
Gozlan Y; Bucris E; Shirazi R; Rakovsky A; Ben-Ari Z; Davidov Y; Veizman E; Saadi T; Braun M; Cohen-Naftaly M; Shlomai A; Shibolet O; Zigmond E; Katchman H; Menachem Y; Safadi R; Galun E; Zuckerman E; Nimer A; Hazzan R; Maor Y; Saif AM; Etzion O; Lurie Y; Mendelson E; Mor O
Antivir Ther; 2019; 24(3):221-228. PubMed ID: 30880684
[TBL] [Abstract][Full Text] [Related]
17. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma.
Sorbo MC; Carioti L; Bellocchi MC; Antonucci F; Sforza D; Lenci I; Ciancio Manuelli M; Armenia D; De Leonardis F; Milana M; Manzia TM; Angelico M; Tisone G; Cento V; Perno CF; Ceccherini-Silberstein F
Liver Int; 2019 Oct; 39(10):1986-1998. PubMed ID: 31172639
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of NS5A resistance associated substitutions in patients with hepatitis C virus genotypes 1a and 3: Impact on current therapeutic strategies.
Grandal M; Pernas B; Tabernilla A; Mariño A; Álvarez H; Valcarce N; Mena A; Castro-Iglesias A; Pérez AB; Delgado M; Poveda E
J Med Virol; 2018 Jun; 90(6):1094-1098. PubMed ID: 29427437
[TBL] [Abstract][Full Text] [Related]
19. Pooled Prevalence of NS5A Resistance-Associated Substitutions in Chronic HCV Genotype 3 Infection: A Study Based on Deposited Sequences in GenBank.
Sharafi H; Ghalamkari S; Hassanshahi A; Alavian SM
Microb Drug Resist; 2019 Sep; 25(7):1072-1079. PubMed ID: 31021305
[TBL] [Abstract][Full Text] [Related]
20. Characterization of
Brandão R; Marcelino R; Gonçalves F; Diogo I; Carvalho A; Cabanas J; Costa I; Brogueira P; Ventura F; Miranda A; Mansinho K; Gomes P
Viruses; 2018 Apr; 10(5):. PubMed ID: 29701642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
